DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Information source: Janssen Pharmaceutical K.K.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Intervention: TMC207 (bedaquiline) (Drug); Background Regimen (BR) (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Janssen Pharmaceutical K.K.

Official(s) and/or principal investigator(s):
Janssen Pharmaceutical K.K. Clinical Trial, Study Director, Affiliation: Janssen Pharmaceutical K.K.

Overall contact:
Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:, Email: JNJ.CT@sylogent.com


The purpose of this study is to explore safety and efficacy of TMC207 administered as part of a multi-drug regimen for 24 to 48-week treatment in Japanese participants with pulmonary multi-drug resistant tuberculosis (MDR-TB), and to evaluate pharmacokinetics (PK) of TMC207 and its primary metabolite M2.

Clinical Details

Official title: An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants With Sputum Culture Conversion

Secondary outcome: Number of Participants With Multidrug resistant (MDRTB) Outcome

Detailed description: This is an open-label (everyone know the study intervention), single-arm, multicenter trial to explore safety, efficacy and PK of TMC207 in Japanese participants with pulmonary MDR-TB. The participants will receive TMC207 for 24 weeks in combination with individualized BR

drugs selected by the Investigator on Day - 1. Participants will primarily be assessed for

sputum culture conversion at Week 24. Safety will be monitored throughout the study.


Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Must have confirmed pulmonary multi-drug resistant tuberculosis (MDR-TB) infection,

which is defined as infection by a strain of M. tuberculosis resistant to both rifampicin and isoniazid (RFP and INH) by previous screening from a TB treatment

- Must have confirmed positive results for acid-fast bacilli (AFB) on direct smear

examination of expectorated sputum specimen (more than [>] 1+ smear-positive) during the Screening Phase or sputum culture positive for M. tuberculosis within the preceding 3 months

- A women must not be of childbearing potential: postmenopausal or permanently

sterilized or otherwise be incapable of pregnancy, or if childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods and a man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control

- Must be willing and able to adhere to the prohibitions and restrictions specified in

this protocol

- Must sign an informed consent form (ICF) indicating that he or she understands the

purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria:

- Has any concomitant severe illness or rapidly deteriorating health condition,

including immune deficiency that would make implementation of the protocol or interpretation of the study results difficult or otherwise make the subject a poor candidate for a clinical study

- Has complicated or severe extra-pulmonary manifestations of TB, including central

nervous system infection

- Participants with significant cardiac arrhythmia requiring medication

- Participants with the abnormal electrocardiogram (ECG) parameters as defined in


- Has human immuno deficiency virus (HIV) antibody positive during the Screening Phase

Locations and Contacts

Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:, Email: JNJ.CT@sylogent.com

Kiyose, Japan; Recruiting

Sakai, Japan; Recruiting

Additional Information

To learn how to participate in this trial please click here.

Starting date: February 2015
Last updated: August 12, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017